Keros Therapeutics Inc (KROS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 09-2020 | 06-2020 | 03-2020 | 12-2019 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -45,361 | -34,685 | -22,649 | -11,892 | -12,336 |
| Depreciation Amortization | 278 | 203 | 131 | 63 | 208 |
| Accounts payable and accrued liabilities | 61 | -372 | 2,764 | -193 | 1,312 |
| Other Working Capital | 2,275 | 1,285 | 1,650 | 2,118 | -6,724 |
| Other Operating Activity | 5,853 | 4,666 | 57 | 1,784 | 1,542 |
| Operating Cash Flow | $-36,894 | $-28,903 | $-18,047 | $-8,120 | $-15,998 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -294 | -234 | -204 | -176 | -271 |
| Investing Cash Flow | $-294 | $-234 | $-204 | $-176 | $-271 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 243,240 | 102,703 | 102,694 | 13 | 14 |
| Other Financing Activity | 52,804 | 53,224 | 53,224 | 55,781 | 0 |
| Financing Cash Flow | $296,044 | $155,927 | $155,918 | $55,794 | $14 |
| Beginning Cash Position | 7,135 | 7,135 | 7,135 | 7,135 | 23,390 |
| End Cash Position | 265,991 | 133,925 | 144,802 | 54,633 | 7,135 |
| Net Cash Flow | $258,856 | $126,790 | $137,667 | $47,498 | $-16,255 |
| Free Cash Flow | |||||
| Operating Cash Flow | -36,894 | -28,903 | -18,047 | -8,120 | -15,998 |
| Capital Expenditure | -294 | -234 | -204 | -176 | -271 |
| Free Cash Flow | -37,188 | -29,137 | -18,251 | -8,296 | -16,269 |